Noxopharm awarded new anti-cancer patent

Pharmaceutical developer Noxopharm has been awarded patent protection for its Veyonda treatment for late-stage cancers. The patent, one of a number of families of patents the company is seeking in major drug markets, is for a suppository formulation including the drug idronoxil. Idronoxil is an inhibitor of sphingosine-1-phosphate (S1P) – a messenger in cells that…